Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has started work with patients on two different application for the repurposed drug Ifenprodil. Moreau telling Proactive how the studies will be conducted for use on IPF and chronic cough and also for the second use for treatment with COVID-19.
Algernon Pharmaceuticals studies on Ifenprodil begins with patients on two fronts
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.28 CAD
Market Cap: $30.82 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...FOR OUR FULL DISCLAIMER CLICK HERE